THIOCTIC ACID MEGLUMINE

Possibly Marketed Outside US

First approved in 2001

Details

Stereochemistry	EPIMERIC
Molecular Formula	C8H14O2S2.C7H17NO5
Molecular Weight	401.539
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCCCC1CCSS1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=QPTVXUUGWBDFLV-WZTVWXICSA-N

InChI=1S/C8H14O2S2.C7H17NO5/c9-8(10)4-2-1-3-7-5-6-11-12-7;1-8-2-4(10)6(12)7(13)5(11)3-9/h7H,1-6H2,(H,9,10);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula	C8H14O2S2
Molecular Weight	206.326
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C7H17NO5
Molecular Weight	195.2136
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19664690 | https://www.ncbi.nlm.nih.gov/pubmed/25104975

Thioctic acid also known as alpha-lipoic acid is a dietary supplement, which is a common ingredient in OTC (over-the-counter) multivitamin formulas and anti-aging supplements. Thioctic acid exists in both R- and S-enantiomeric forms, however, only R-form is essential as a cofactor in biological systems (the acid is coupled via an amide linkage to a lysine of several multienzyme complexes, such as the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, the glycine cleavage system and the branched-chain oxo acid dehydrogenase complex). Most commercially available thioctic acid supplements are a mixture of both R and S enantiomers or R-form alone. Several studies have shown that the acid has beneficial effect on diabetes complications, cancer, glaucome, liver disease, etc. The mechanisms of thioctic acid is related to its antioxidant properties, metal chelator properties, however, those mechanisms need futher confirmation.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.altmedrev.com/publications/11/3/232.pdf	Palliative	Phase IV 63	Unknown Approved Use Unknown
Nonalcoholic steatohepatitis 9 Sources: https://www.clinicaltrials.gov/ct2/show/NCT01406704	Primary	Phase IV 63	Unknown Approved Use Unknown
Subchorionic hematoma 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02601898	Primary	Phase IV 63	Unknown Approved Use Unknown
Stress (tako-tsubo) cardiomyopathy 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT01524861	Primary	Phase IV 63	Unknown Approved Use Unknown
Women infertility 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT03023514	Primary	Phase IV 63	Unknown Approved Use Unknown
Carpal tunnel syndrome 3 Sources: https://www.clinicaltrials.gov/ct2/show/NCT01895621	Palliative	Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
7.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30241687/	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		THIOCTIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
5.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30241687/	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		THIOCTIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30241687/	600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		THIOCTIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/	Disc. AE: Gastrointestinal disturbance... AEs leading to discontinuation/dose reduction: Gastrointestinal disturbance (8.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/
600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/	Other AEs: Itching... Other AEs: Itching (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/
600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/	Disc. AE: Skin eruption... AEs leading to discontinuation/dose reduction: Skin eruption (10%) Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/

AEs

AE	Significance	Dose	Population
Gastrointestinal disturbance	8.2% Disc. AE	600 mg 1 times / day multiple, oral Recommended Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/15120701/
Itching	0.8%	600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21187189/
Skin eruption	10% Disc. AE	600 mg 3 times / day multiple, oral Recommended Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/27276401/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 1060 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 BSEP 550 P-gp 1741 OATP1B3 961 OATP1B1 1079 CYP19A1 429 BCRP 910 CYP3A 227	P-gp 2052	GLUT1 14 GLUT4 5

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTM0MzQyIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTM0MzQyIn19	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	no [IC50 >1000 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 69.0	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 346.0	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 71.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEzNDM0MiJ9fQ==	yes [Inhibition 10 uM]
CYP3A 317	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18838505/	yes
GLUT1 20	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/23984871/	yes
GLUT4 20	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/23984871/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/864#section=BioAssay-Results Page: 448 \| 449	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTM0MzQyIn19

PubMed

Title	Date	PubMed
Crystalline alpha-lipoic acid; a catalytic agent associated with pyruvate dehydrogenase.	1951 Jul 27	14854913
Human placental Na+-dependent multivitamin transporter. Cloning, functional expression, gene structure, and chromosomal localization.	1999 May 21	10329687
Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions.	2000	10966480
The antioxidant effect of DL-alpha-lipoic acid on copper-induced acute hepatitis in Long-Evans Cinnamon (LEC) rats.	2001 Jan	11234997
New metabolic pathways of alpha-lipoic acid.	2001 Jun	11353754
Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats.	2001 Sep	11596663
Lipoic acid in combination with a chelator ameliorates lead-induced peroxidative damages in rat kidney.	2002 Aug	12185410
The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells.	2002 Jun	12180195
Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy.	2002 May	12110042
Combined efficacies of lipoic acid and meso-2,3-dimercaptosuccinic acid on lead-induced erythrocyte membrane lipid peroxidation and antioxidant status in rats.	2003 Apr	12755469
Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.	2003 Nov	14551180
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.	2004 Aug	15309289
L-carnitine and DL-alpha-lipoic acid reverse the age-related deficit in glutathione redox state in skeletal muscle and heart tissues.	2004 Jul	15246746
Alpha-lipoic acid increases Na+K+ATPase activity and reduces lipofuscin accumulation in discrete brain regions of aged rats.	2004 Jun	15247042
[Effects of DL-alpha-lipoic acid on the experimentally induced diabetic cataract in rats].	2004 Mar	15307993
Synthesis and characterization of new and potent alpha-lipoic acid derivatives.	2004 Mar 1	14980629
Peroxide-mediated desulfurization of phosphorothioate oligonucleotides and its prevention.	2005 Feb	15614814
Beneficial effects of DL-alpha-lipoic acid on cyclophosphamide-induced oxidative stress in mitochondrial fractions of rat testis.	2005 Feb 28	15766923
Protein oxidative damage in arsenic induced rat brain: influence of DL-alpha-lipoic acid.	2005 Jan 15	15585356
Syntheses of novel indole lipoic acid derivatives and their antioxidant effects on lipid peroxidation.	2005 Mar	15765493
(R)-alpha-lipoic acid protects retinal pigment epithelial cells from oxidative damage.	2005 Nov	16249512
Decrease in NADPH-cytochrome P450 reductase activity of the human heart, Liver and lungs in the presence of alpha-lipoic acid.	2006	16391466
Oxidative stress-mediated macromolecular damage and dwindle in antioxidant status in aged rat brain regions: role of L-carnitine and DL-alpha-lipoic acid.	2006 Jun	16480704
MafA expression and insulin promoter activity are induced by nicotinamide and related compounds in INS-1 pancreatic beta-cells.	2006 Mar	16505238
Modulatory role of lipoic acid on adriamycin-induced testicular injury.	2006 Mar 25	16434030
Interfacial pH and surface pKa of a thioctic acid self-assembled monolayer.	2006 Nov 7	17043716
Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes.	2006 Oct 31	17079870
Application of N-PLS calibration to the simultaneous determination of Cu(2+), Cd(2+) and Pb(2+) using peptide modified electrochemical sensors.	2006 Sep	17047806
Insight into the role of DL-alpha-lipoic acid against cyclophosphamide induced alterations in calcium sensitivity of cardiac myofilaments.	2006 Sep	16625422
Diabetic painful neuropathy: current and future treatment options.	2007	17352515
Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice.	2007 Feb	17255331
Monolayer-protected gold nanoparticles by the self-assembly of micellar poly(ethylene oxide)-b-poly(epsilon-caprolactone) block copolymer.	2007 Feb 13	17279704
Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: protection by (R)-alpha-lipoic acid.	2007 Jan	17197552
Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT.	2007 Jan	17044076
CoCl2 induces protective events via the p38-MAPK signalling pathway and ANP in the perfused amphibian heart.	2007 Jul	17575032
Beneficial effect of DL-alpha-lipoic acid on cyclosporine A induced hyperlipidemic nephropathy in rats.	2007 Jul	17225189
Adjunctive care with nutritional, herbal, and homeopathic complementary and alternative medicine modalities in stroke treatment and rehabilitation.	2007 Jul-Aug	17698456
Unusual fluorescence enhancement of a novel carbazolyldiacetylene bound to gold nanoparticles.	2007 Jun 5	17488044
Effect of DL-alpha-lipoic acid on cyclophosphamide induced lysosomal changes in oxidative cardiotoxicity.	2007 May 1	17418239
Efficacy of DL-alpha-lipoic acid on methanol induced free radical changes, protein oxidative damages and hsp70 expression in folate deficient rat nervous tissue.	2007 May 1	17399694
Therapeutic efficacy of DL-alpha-lipoic acid on cyclosporine A induced renal alterations.	2007 Oct 1	17619014
Potent upregulation of glutathione and NAD(P)H:quinone oxidoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: protection against neurotoxicant-elicited cytotoxicity.	2008 May	17940886

Patents

Sample Use Guides

In Vivo Use Guide

Recommended oral therapeutic dosages of alpha-lipoic acid range from 600-1800 mg daily.

Route of Administration: Oral

In Vitro Use Guide

Supplementation of Human Umbilical Vein Endothelial Cells with 100, 200, or 500 uM thioctic acid after inoculation with R. rickettsii restored the intracellular levels of thiols and glutathione peroxidase and reduced the intracellular peroxide levels in infected cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:56:55 GMT 2025` Edited by `admin` on `Mon Mar 31 21:56:55 GMT 2025`
Record UNII	146TUC9N9F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

THIOCTIC ACID MEGLUMINE

Common Name

English

.ALPHA.-LIPOIC ACID MEGLUMINE

Preferred Name

English

1,2-DITHIOLANE-3-PENTANOIC ACID, COMPD. WITH 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL (1:1)

Common Name

English

D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, 1,2-DITHIOLANE-3-PENTANOATE (1:1) (SALT)

Systematic Name

English

ALPHA-LIPOIC ACID, MEGLUMINE SALT

Common Name

English

Thioctic acid meglumine [WHO-DD]

Common Name

English

.ALPHA.-LIPOIC ACID, MEGLUMINE SALT

Common Name

English

Code System Code Type Description

PUBCHEM

91668164